Ixoberogene soroparvovec explained

Ixoberogene soroparvovec (also known as ADVM-022), is a gene therapy developed by Adverum Biotechnologies for wet age-related macular degeneration. It is delivered via the viral vector AAV.7m8.[1] [2]

Notes and References

  1. Gelfman . Claire M. . Grishanin . Ruslan . Bender . Kristina Oresic . Nguyen . Aivan . Greengard . Judith . Sharma . Pallavi . Nieves . Julio . Kiss . Szilárd . Gasmi . Mehdi . Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema . Journal of Ocular Pharmacology and Therapeutics . 37 . 3 . 2021-04-01 . 1080-7683 . 33835848 . 8060718 . 10.1089/jop.2021.0001 . 181–190.
  2. Grishanin . Ruslan . Vuillemenot . Brian . Sharma . Pallavi . Keravala . Annahita . Greengard . Judith . Gelfman . Claire . Blumenkrantz . Mark . Lawrence . Matthew . Hu . Wenzheng . Kiss . Szilárd . Gasmi . Mehdi . Preclinical Evaluation of ADVM-022, a Novel Gene Therapy Approach to Treating Wet Age-Related Macular Degeneration . Molecular Therapy . January 2019 . 27 . 1 . 118–129 . 10.1016/j.ymthe.2018.11.003. 30528929 . free . 6319194 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Ixoberogene soroparvovec".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.